News | November 17, 2008

Damage Inflicted During Cardiac Attacks More Widespread than Previously Thought

November 18, 2008 - Cholesterol crystals released in the bloodstream during a cardiac attack or stroke can damage artery linings much further away from the site of the attack, leaving survivors at greater risk than previously thought, say researchers from Michigan State University.

George Abela, M.D., in Michigan State University's College of Human Medicine and chief of the department of medicine's cardiology section, is leading innovative research into the role that the crystallization and expansion of cholesterol play in heart attacks, strokes and other cardiovascular events in humans. He presented his latest research last week at the American Heart Association's 2008 Scientific Sessions meeting in New Orleans.
In recent medical trials, Abela and his team of researchers tested carotid arteries in a laboratory by injecting cholesterol crystals into them.

"Cholesterol has been shown to expand when crystallizing and then be released into the circulation following a cardiac event," Dr. Abela said. "We found that the flow of sharp-ended crystals in arteries damage the lining of arteries and decrease the ability of arteries to dilate properly at intervals far away from the site of the attack."

Abela compared the process to a tree, with the trunk as the site of the cardiac event and the branches representing arteries where damage is afflicted far away from the trunk.

"These findings have important clinical implications," Abela said. "We found the original injury was being transmitted downstream. We may need to expand the testing that we have patients undergo to make sure more damage is not being done during a cardiac attack or stroke."

For more information: www.msu.edu


Additional Content

News | Cardiovascular Clinical Studies

Nov. 1, 2026 – Abbott has announced the 30-day results from the TECTONIC Coronary Artery Disease (CAD) Intravascular ...

Home November 03, 2026
Home
News | Cardiovascular Clinical Studies

Oct. 27, 2026 — Atrium Therapeutics, developer of RNA therapeutics targeted to the heart, has announced that the first ...

Home October 30, 2026
Home
News | Cardiovascular Clinical Studies

Oct. 1, 2026 — W. L. Gore & Associates’ medical business (Gore) has announced the first patient enrollment in the IBE ...

Home October 01, 2026
Home
News | Cardiovascular Clinical Studies

Aug. 31, 2026 — Amgen has announced new findings showing Repatha (evolocumab) reduced the risk of death in high-risk ...

Home September 02, 2026
Home
News | Cardiovascular Clinical Studies

Aug. 20, 2026 — A new study found that nearly 8 out of 10 young adult participants, average age 23 years, had ...

Home August 21, 2026
Home
Subscribe Now